Dilated cardiomyopathy: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• DMD 0
• SGLT2 0
• TP53 0
• IL-17 0
• NRF2 0
• CD40 0
• ERK 0
• GLP-1 0
• IL-1 0
• IL-6 0
• mTOR 0
• NLRP3 0
• PI3K 0
• PINK1 0
• PPAR 0
• RUNX1 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 660 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study

  NCT04331769· Ancora Heart, Inc.· Updated 3 Jun 2026

  “Recruitment on hold pending modifications to the clinical investigation plan”Registry text, quoted unchanged. Source

• Terminated

  Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

  NCT04572893· Bristol-Myers Squibb· Updated 21 May 2025

  “Business objectives have changed”Registry text, quoted unchanged. Source

• Terminated

  New Horizons for the Treatment of Cardiomyopathy in Children

  NCT04893629· Damascus University· Updated 20 Feb 2025

  “lack of necessary equipment”Registry text, quoted unchanged. Source

• Withdrawn

  Ventricular Sling for Heart Failure With Reduced Ejection Fraction

  NCT04475315· University of Miami· Updated 11 May 2022

  “Difficulty with recruitment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

  NCT06356727· Azienda Ospedaliera Universitaria Integrata Verona· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Observational Study of Natural History of BAG3 Gene Mutation-Associated Dilated Cardiomyopathy in Chinese Adults

  NCT07646600· AstraZeneca· Source

• A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

  NCT07241104· AstraZeneca· Source

• ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

  NCT07218887· Alexion Pharmaceuticals, Inc.· Source

• A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

  NCT06464588· Emory University· Source

• A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

  NCT05981092· Alexion Pharmaceuticals, Inc.· Source

• AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

  NCT06699056· Peerbridge Health, Inc· Source

• Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy

  NCT03843255· Imperial College London· Source

• UIC Multi-Ethnic DCM Registry

  NCT07145138· University of Illinois Chicago· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Organoids 1
• Mendelian Randomization Analysis 8
• CRISPR-Cas Systems 2
• Gene Expression Profiling 23
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 11
• Proteomics 9
• Metabolomics 3
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 20
• Machine Learning 8
• Deep Learning 2
• Cohort Studies 15
• Genome-Wide Association Study 11

• Identification of a Lactylation-Related Gene Signature and Candidate Biomarkers for Dilated Cardiomyopathy.

  J Cell Mol Med, Sept 2026

• Identification of Aging and Mitochondria-Related Hub Genes in Dilated Cardiomyopathy.

  J Vis Exp, Aug 2026

• Common Molecular Mechanisms and Candidate Drug Targets in Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease.

  J Vis Exp, Aug 2026

• Metabolic Task Analysis Reveals Distinct Metabotypes in End-Stage Dilated Cardiomyopathy.

  Circ Genom Precis Med, Jul 2026

• An integrated cell atlas of 2.4 million cardiac cells across 209 individuals in health and disease.

  Nat Cardiovasc Res, Jun 2026

• Unveiling CTGF and APOA1: key hub genes and therapeutic targets in dilated cardiomyopathy.

  J Cardiothorac Surg, May 2026

• Identification of diagnostic and therapeutic roles of programmed cell death-related proteins in dilated cardiomyopathy: a multi-omics and experimental validation study.

  Sci Rep, May 2026

• Zebrafish Model Reveals Early Electrocardiographic and Molecular Signatures of Doxorubicin-Induced Cardiotoxicity.

  Cardiovasc Toxicol, Apr 2026

• Genetic diagnosis of sibling cases initiated by identification of outlier gene expression using transcriptome analysis of urine-derived cells.

  J Hum Genet, Mar 2026

• Identification of potential hub genes related to ferroptosis and hypoxia in dilated cardiomyopathy: a bioinformatic analysis with preliminary experimental validation.

  Exp Biol Med (Maywood), Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.